Abbvie M19-939 (budigalimab phase 1 study)
| Study type | Summary | Inclusion Criteria | Participation requirements | Status |
| Randomised placebo-controlled study | Phase 2 of this international study is being conducted in Melbourne. Participants will receive 4 intravenous infusions of either budigalimab (a drug being studied to treat cancer known as an immune checkpoint blocker) or a placebo. This study involves a closely monitored 12-week treatment interruption. There are strict criteria to restart HIV treatment to ensure participant safety. | · HIV+ · Adults 18-65 years · On HIV treatment for >12 months · plasma RNA < 50 copies/mL for > 6 months · CD4 >500 | Participants will receive 4 intravenous infusions of either budigalimab (a drug being studied to treat cancer known as an immune checkpoint blocker) or a placebo. Participants will need to attend approximately 19 study visits over a 5-6 month period. During the treatment interruption, participants are monitored every 1-2 weeks. | Currently recruiting |
.png)